• AlzeCure receives approval to start clinical Phase Ib trial with ACD440 in neuropathic pain

  • See the latest presentation with CEO Martin Jönsson when he is interviewed by Aktiespararnas Analysguiden.

  • Alzecure is highlighted in a report on research on Alzheimer’s and neurodegenerative diseases

  • AlzeCure Pharma develops novel analgesic drug based on Nobel prize-winning discoveries

  • AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13

AlzeCure Pharma

AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders


AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction

Alzheimer’s Disease

Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.